Document is current
Any future updates will be listed below
-
Authors
Heindl, F.
Traschütz, A.
Synofzik, M.
Wirth, T.
Anheim, M.
Tarnutzer, A. A.
Hartmann, A. M.
Rujescu, D.
Giegling, I.
Feil, K.
Adrion, C.
Strupp, M.
-
Funding
Funding for this research was provided by:
Klinikum der Universität München
- License Information
-
More Information
Article History
Received: 10 January 2026
Accepted: 11 March 2026
First Online: 10 April 2026
Declarations
:
: F. Heindl, A. Traschütz, A.M. Hartmann, I. Giegling and C. Adrion declare no conflicts of interest. M. Strupp is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He has received speaker’s honoraria from Abbott, Auris Medical, Biogen, Eisai, Grünenthal, GSK, Henning Pharma, Interacoustics, J&J, MSD, NeuroUpdate, Otometrics, Pierre-Fabre, TEVA, UCB, and Viatris. He received support for clinical studies from Decibel, U.S.A., Cure within Reach, U.S.A. and Heel, Germany. He distributes “M-glasses” and “Positional vertigo App”. He acts as a consultant for Bulbitec, Heel and Vertify. He is a scientific founder, investor and share-holder of IntraBio.M. Synofzik has received consultancy honoraria from UCB, Prevail, Orpha zyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly, Quince, Neurocrine, Insmed, and Solaxa, all unrelated to the present manuscript.T. Wirth reported grants from Direction Générale de l’Offre de soins, France Parkinson, and Association Connaitre les Syndromes Cérébelleux, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, Ipsen and Biogen, payment for expert testimony from Abbvie, Support for attending meetings and/or travel from Homeperf, Lundbeck and The Movement Disorders Society.A. A. Tarnutzer has received consultant and/or speaker fees from Mitsubishi Tanabe Pharma, AstraZeneca, Teva Pharma, Neuraxpharma, Angelini Pharma and Schwabe Pharma, all unrelated to the present manuscript.D. Rujescu served as consultant for Boehringer-Ingelheim and Janssen, received honoraria from Boehringer-Ingelheim, Gerot Lannacher, Indorsia, Janssen and Pharmagenetix, received research/travel support from Angelini, Boehringer-Ingelheim, Janssen and Schwabe, and served on advisory boards of AC Immune, Boehringer-Ingelheim, Indorsia, Roche and Rovi.
